Silence Therapeutics (NASDAQ:SLN) Rating Reiterated by Morgan Stanley

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “overweight” rating restated by equities research analysts at Morgan Stanley in a report issued on Monday, Benzinga reports. They currently have a $45.00 target price on the stock. Morgan Stanley’s price objective points to a potential upside of 99.91% from the stock’s current price.

Other analysts also recently issued research reports about the company. BMO Capital Markets started coverage on Silence Therapeutics in a research note on Wednesday, January 31st. They set an “outperform” rating and a $67.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, March 15th. Finally, Chardan Capital boosted their price target on Silence Therapeutics from $26.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 14th.

Silence Therapeutics Stock Up 0.0 %

Shares of SLN stock opened at $22.51 on Monday. Silence Therapeutics has a 1-year low of $4.55 and a 1-year high of $27.72. The stock’s fifty day moving average price is $23.02 and its 200 day moving average price is $17.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.56 and a quick ratio of 4.56. The company has a market cap of $673.72 million, a price-to-earnings ratio of -15.42 and a beta of 1.41.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.22). Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. The business had revenue of $2.61 million for the quarter, compared to analysts’ expectations of $11.46 million. On average, research analysts expect that Silence Therapeutics will post -1.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SLN. Lynx1 Capital Management LP acquired a new position in shares of Silence Therapeutics in the 3rd quarter valued at about $2,315,000. SG Americas Securities LLC acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at about $110,000. Vivo Capital LLC acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at about $8,862,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after buying an additional 40,063 shares during the period. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.